1Judy J, Rhoderick M, Christopher R, et al. The utlity of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease [J]. The American of Surgery. 2010,199(3), 294-298.
7Fiore E, Rago T, Provenzale MA,et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular dis- ease:thyroid autonomy may play a protective role[J]. Endocrine-Related Cancer 2009,16(4) : 1251-1260.
8Kasiji K.Epidemiology of thyroid tumors:effect of environmental iodine intake.Nippon Rinsho,2007,65:1953-1958.
9Hollowell JG,Stachling NW,Flanders WD,et al.Serum TSH,T (4),and thyroid antibodies in the United States population (1998 to 1994):National Health and Nutrition Examination Survey(NHANES Ⅲ).J Clin Endocrinol Metab,2002,87:489-499.
10Li Y,Teng D,Shan Z,et al.Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow up survey of populations with different iodine intakes.J Clin Endoerinol Metab,2008,93:1751-1757.
3Hamilton TE. Thyrotropin Levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thy- roid disease:Implications for the diagnosis of subclinical hypothyroidism [J]. J Clin Endoerinol Metab,2008,93 (4) : 1224-1230.
4Ismail AA. Thyroid stimulating hormone cut -off to define subclinical hypothyroidism [J]. Ann Clin Biochem, 2009,46 (Pt5) : 426-429.
